Psoriasis – Pipeline Review, H2 2019 :

Research By Markets adds Market Research Report - Psoriasis – Pipeline Review, H2 2019 :

For detailed information:

Psoriasis – Pipeline Review, H2 2019


Psoriasis – Pipeline Review, H2 2019, provides an overview of the Psoriasis (Immunology) pipeline landscape.

Psoriasis is a chronic skin condition caused by an overactive immune system. Symptoms of the disease include shedding of cells, flared up skin, itchiness, and burning sensation, swollen and stiff joints. Predisposing factors include heredity, side effects of certain medicines, stress, infections and environmental conditions. The condition may be controlled by topical or systemic medications and phototherapy.

Report Highlights

Psoriasis – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Psoriasis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Psoriasis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 11, 1, 25, 38, 62, 3, 126, 41 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 4 molecules, respectively.

Psoriasis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


– The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriasis (Immunology).
– The pipeline guide reviews pipeline therapeutics for Psoriasis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Psoriasis (Immunology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Psoriasis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Psoriasis (Immunology)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Psoriasis (Immunology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Psoriasis (Immunology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned:
3SBio Inc
AbbVie Inc
Abcentra LLC
AbClon Inc
Abeome Corp
AbGenomics International Inc
Abivax SA
Accuitis Pharmaceuticals Inc
Aclaris Therapeutics Inc
Actinobac Biomed Inc
ActoBio Therapeutics Inc
Aerie Pharmaceuticals Inc
Affibody AB
Affilogic SAS
Agragen LLC
Akeso Biopharma Inc
Alfacyte Ltd
Allianz Pharmascience Ltd
Almirall SA
Aluda Pharmaceuticals Inc
Alvotech ehf
AmDerma Pharmaceuticals LLC
Amgen Inc
AnaptysBio Inc
AntalGenics SL
AnTolRx Inc
Apidel SA
Apimeds Inc
Applied Biology Inc
Arbor Pharmaceuticals LLC
Arcutis Inc
Arrien Pharmaceuticals LLC
AstraZeneca Plc
Athenex Inc
Atlantic Bio Sci LLC
Aurigene Discovery Technologies Ltd
Bayer AG
Beijing Fogangren Bio-Pharm Tech Co Ltd
Beijing Guiqianjin Medical Technology Co Ltd
Beijing Northland Biotech Co Ltd
BioApex sro
Biocon Ltd
BioLingus AG
Biomendics LLC
Biomimetix JV LLC
BioXpress Therapeutics SA
BirchBioMed Inc
Boehringer Ingelheim International GmbH
Boston Pharmaceuticals Inc
Botanix Pharmaceuticals Ltd
Brickell Biotech Inc
Bristol-Myers Squibb Co
c-a-i-r Biosciences GmbH
C4X Discovery Holdings Plc
CalciMedica Inc
Can-Fite BioPharma Ltd
Canvax Biotech SL
Celgene Corp
Celon Pharma SA
CheckPoint Immunology Inc
ChemoCentryx Inc
ChironWells GmbH
Coegin Pharma AS
Coherus BioSciences Inc
Compugen Ltd
Concenter BioPharma Silkim Ltd
Crescita Therapeutics Inc
Curapel Ltd
Cythera Inc
Daiichi Sankyo Co Ltd
Dalriada Therapeutics Inc
Dermavant Sciences Inc
DM Bio Ltd
DNX Biopharmaceuticals Inc
Dr. August Wolff GmbH & Co KG Arzneimittel
Eli Lilly and Co
Emeriti Pharma AB
Escalier Biosciences BV
Eternity Bioscience Inc
Evelo Biosciences Inc
Exicure Inc
Fujifilm Kyowa Kirin Biologics Co Ltd
FunPep Co Ltd
FYB202 GmbH & Co KG
Galapagos NV
Galderma SA
Genentech Inc
GeneScience Pharmaceuticals Co Ltd
Genfit SA
Genrix (Shanghai) Biopharmaceutical Co Ltd
GlaxoSmithKline Plc
GlycoMar Ltd
Helix BioMedix Inc
Hengenix Biotech Inc
HitGen LTD
Huabo Biopharm Co Ltd
Hualan Biological Engineering Inc
Hydra Biosciences Inc
Hypo-Stream Ltd
IMGENEX India Pvt Ltd
Immune Pharmaceuticals Inc
Immungenetics AG
Immunic Inc
Immunwork Inc
Innovimmune Biotherapeutics Inc
InSight Biopharmaceuticals Ltd
Inspyr Therapeutics Inc
Instituto Biomar SA
Istesso Ltd
Japan Tobacco Inc
JHL Biotech Inc
Jiangsu Hengrui Medicine Co Ltd
JiangSu Qyuns Therapeutics Co Ltd
Johnson & Johnson
JS InnoPharm (Shanghai) Ltd
Jubilant Biosys Ltd
Kadmon Corp LLC
Kaken Pharmaceutical Co Ltd
Kang Stem Biotech Co Ltd
Kangpu Biopharmaceuticals Ltd
Kine Sciences
Krystal Biotech Inc
Kv1.3 Therapeutics
Kymab Ltd
Lead Pharma Holding BV
Leo Pharma AS
Link Health Group
Lipidor AB
Lupin Ltd
Lycera Corp
Machavert Pharmaceuticals LLC
Maruho Co Ltd
Matrisys Bioscience Inc
MC2 Therapeutics AS
Merck KGaA
Metrion Biosciences Ltd
MetrioPharm AG
Mical Pharmaceuticals LLC
Midatech Pharma Plc
Mycenax Biotech Inc
Nektar Therapeutics
Nepsone ehf
Nestle Skin Health SA
NeuClone Pty Ltd
Nichi-Iko Pharmaceutical Co Ltd
Nimbus Therapeutics LLC
Nordic Group BV
NovaLead Pharma Pvt Ltd
Novan Inc
Novartis AG
Numab Innovation AG
Octagon Therapeutics Inc
One World Cannabis Ltd
Orphagen Pharmaceuticals Inc
OSE Immunotherapeutics
P & S Nano Ltd
Palo BioFarma SL
Panaxia Pharmaceutical Industries Ltd
Par’Immune SAS
Pfizer Inc
Philogen SpA
PinCell srl
Pivot Pharmaceuticals Inc
Polpharma Biologics
PRCL Research Inc
Principia Biopharma Inc
Progenra Inc
Promethera Biosciences SA
Provectus Biopharmaceuticals Inc
Pyramid Biosciences Inc
Reata Pharmaceuticals Inc
RedHill Biopharma Ltd
Rheos Medicines Inc
Rigel Pharmaceuticals Inc
RNAx Ltd
Samumed LLC
Sareum Holdings Plc
SBI Biotech Co Ltd
selectION Inc
Servatus Ltd
SFA Therapeutics LLC
Shandong Danhong Pharmaceutical Co Ltd
Shanghai Celgen Bio-Pharmaceutical Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shulov Innovative Science Ltd
Siam Bioscience Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Sienna Biopharmaceuticals Inc
Singh Biotechnology LLC
Sinocelltech Ltd
Soligenix Inc
Spherium Biomed SL
sterna biologicals Gmbh & Co KG
Sun Pharma Advanced Research Company Ltd
Sunny BioDiscovery Inc
Suzhou Connect Biopharmaceuticals Ltd
Syntrix Biosystems Inc
Taro Pharmaceuticals USA Inc
Temisis Therapeutics
Tianjin Ever Union Biotechnology Co Ltd
Tianjin Hemay Bio-Tech Co Ltd
Tonghua Dongbao Pharmaceutical Co Ltd
V Clinbio LLC
Vidasym Inc
Visionary Pharmaceuticals Inc
vTv Therapeutics Inc
Welichem Biotech Inc
Wellstat Therapeutics Corp
Wuhan Institute of Biological Products Co Ltd
XBiotech Inc
Yuhan Corp
Zai Lab Ltd
Zhejiang Hisun Pharmaceutical Co Ltd

For queries regarding this report:

Contact Us:
Sales Desk
USA: +1-800-416-3124

Follow us on Social Media:

Ritesh Tiwari is the Founder of Research By Markets, a leading Market Research Reports Reseller trusted by Fortune listed companies for their requirements of Syndicated and Custom Market Research Reports. Ritesh has an overall experience of 18+ years in Recruitments, Sales and Operations. He has been associated with the Market Research industry for the past 7 years. He is an avid foodie as well as a huge football fan being a supporter of Manchester United (EPL) and FC Barcelona (La Liga). Get in touch with him via *Market Research News is a part of Research By Markets.